The UMass Center for Clinical and Translational Science (UMCCTS) and Pfizer's Center for Therapeutic Innovation (CTI) announce the
2nd Annual CTI Request for Proposals
To view the September 17, 2012 Pfizer powerpoint presentation click here.
The deadline for submission of a 2 page, non-confidential pre-proposal in the required format will be due on or before October 19th, 2012, 5:00 PM (EST) to Nate Hafer, Nathaniel.Hafer@umassmed.edu. Click here to obtain the Pre-Proposal template/instructions.
To register, please visit: https://cti.ideareach.com/ and create a user profile.
The Pfizer CTI PowerPoint presentation that was discussed on the September 17th, can be downloaded here. Full proposal information can be viewed at: http://www.umassmed.edu/Content.aspx?id=160832
The UMCCTS is excited to announce a Request for Proposals (RFP) for this year’s round of funding from Pfizer’s Center for Therapeutic Innovation (CTI). CTI is an innovative Pfizer program that partners with leading academic medical centers nationwide to accelerate the translation of novel biomedical insights to the clinic. CTI enables translational medicine by accelerating research and development of discoveries from target identification to proof of mechanism in a Phase 1 clinical trial. Core elements of the CTI partnership with UMCCTS include:
Focus on protein therapeutics (e.g., monoclonal antibodies, antibody variants, recombinant proteins, Fc-fusion, pegylated proteins, antibody and protein conjugates, bi-specific antibodies and peptides)
Focus on understanding patient heterogeneity and stratification
Equitable IP and publication rights
Joint Steering Committee governance with equal representation from UMCCTS and Pfizer
Co-location of scientists, technology and drug development expertise
Collaborative use of Pfizer’s proprietary drug discovery tools and technologies
Support for IND- & clinical-enabling functions (toxicology, regulatory, etc.)
Success-based funding/financial incentives (milestone & royalty payments)
The goal of a funded CTI program is to establish proof of mechanism in the clinic for a new therapeutic that may be licensed to Pfizer and commercialized to treat patients with unmet medical needs.
For the 2012 RFP, CTI is focused on the development of protein therapeutics in three main disease areas:
Autoimmunity (especially Systemic Lupus Erythematosus / Lupus Nephritis)
Renal Disease (Kidney Injury/Lupus Glomerulonephritis, IgA Nephropathy)
Cardiovascular (Congestive Heart Failure, Post-Myocardial Infarction and Acute Coronary Syndrome)
A two-page, non-confidential pre-proposal in the required format must be submitted to the UMCCTS on or before October 19, 2012. UMCCTS scientists whose pre-proposals are selected for further consideration will be invited to submit a full proposal that may be written in collaboration with Pfizer scientists to be evaluated for funding by the CTI Steering Committee. All researchers, clinicians and post-docs may apply.